Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Dow
Express Scripts
Medtronic
Johnson and Johnson
McKesson
Colorcon

Last Updated: January 17, 2022

DrugPatentWatch Database Preview

Investigational Drug Information for Samidorphan


Email this page to a colleague

« Back to Dashboard

What is the drug development status for Samidorphan?

Samidorphan is an investigational drug.

There have been 6 clinical trials for Samidorphan. The most recent clinical trial was a Phase 2 trial, which was initiated on May 1st 2014.

The most common disease conditions in clinical trials are Schizophrenia, Disease, and Alcoholism. The leading clinical trial sponsors are Alkermes, Inc. and [disabled in preview].

There are forty-four US patents protecting this investigational drug and two hundred and thirty-eight international patents.

Recent Clinical Trials for Samidorphan
TitleSponsorPhase
Phase 1 Study of OLZ/SAM in Pediatric Subjects With Bipolar I DisorderAlkermes, Inc.Phase 1
A Phase 1 Safety Study in Adults With SchizophreniaAlkermes, Inc.Phase 1
A Study of [14c]-Samidorphan (Also Known as ALKS 33) in Healthy, Male VolunteersAlkermes, Inc.Phase 1

See all Samidorphan clinical trials

Clinical Trial Summary for Samidorphan

Top disease conditions for Samidorphan
Top clinical trial sponsors for Samidorphan

See all Samidorphan clinical trials

US Patents for Samidorphan

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Samidorphan ⤷  Try it Free Composition comprising a therapeutic agent and a respiratory stimulant and methods for the use thereof ⤷  Try it Free
Samidorphan ⤷  Try it Free Controlled release dosage form TRIASTEK, INC. (Nanjing, CN) ⤷  Try it Free
Samidorphan ⤷  Try it Free Compositions of buprenorphine and .mu. antagonists Alkermes Pharma Ireland Limited (Dublin, IE) ⤷  Try it Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Samidorphan

Drugname Country Document Number Estimated Expiration Related US Patent
Samidorphan European Patent Office EP3324975 2035-07-22 ⤷  Try it Free
Samidorphan European Patent Office EP3801545 2035-07-22 ⤷  Try it Free
Samidorphan World Intellectual Property Organization (WIPO) WO2017015309 2035-07-22 ⤷  Try it Free
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Express Scripts
Medtronic
Johnson and Johnson
McKesson
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.